Clinical Management
Clinical ManagementCME/CE Activity
Complications of HIV/HAART: A Summary of Key CROI 2008 Research
|
ACTIVITY LINKS
|
This continuing-education activity consists of one 42-minute podcast (or the written summary; see Required Materials section below), an accompanying slide set and a post-test consisting of 4 questions. The full activity should take approximately 50 minutes to complete. Once you have listened to the podcast or read the written summary, scored 70% or higher on this activity's post-test and completed the post-test evaluation, you will be eligible to receive:
- Physicians: Up to 1.0 hours of AMA PRA category 1 credit.
- Pharmacists: Up to 1.0 hours of pharmacy credit.
- Nurses: Up to 1.0 hours of Nursing Continuing Education contact credit (or 1.25 hours of California Board of Registered Nursing credit).
This activity was released on February 11, 2008. Credit for successfully completing this activity will be available until February 11, 2009.
Unsure if you can earn credit for this activity? Read the "Credit information for ..." sections for more information.
This activity is jointly sponsored by Postgraduate Institute for Medicine and The Body PRO.
For information about the accreditation of this program, please contact PIM at 303.799.1930 or information@pimed.com.
This continuing-education activity is funded by an educational grant from Tibotec Therapeutics.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and The Body PRO. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)?. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing-education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number: 809-999-08-036-H02-P)
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within 8 weeks (if applicable).
Nursing Continuing Education
CNA/ANCC: This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine (PIM).
PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
California Board of Registered Nursing: Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 1.25 contact hours.
Fee Information
There is no fee for this educational activity.
At the heart of this activity is a research summary available in two different formats: MP3 audio and a written transcript. You can use either of these two formats to complete this activity.
In addition to the audio/written summary, an accompanying slide set is also provided, and is required material for this activity.
Read/Listen to This Activity
- Read Written Summary (includes links to audio and slides)
- Listen to Podcast (42 min.)
- Download PowerPoint Slide Set
- Listen to Audio With Slides
This continuing-education activity is funded by an educational grant from Tibotec Therapeutics.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
David Wohl, M.D., the faculty member involved in this activity, has been a consultant for Abbott Laboratories, Tibotec and Merck & Co. He has served on speakers bureaus for Abbott, Gilead, Roche Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec and Merck. In addition, he has received research support from Abbott, Roche and Merck.
Click here for a brief biography of Dr. Wohl.
Jan Hixon, RN, BSN, MA (PIM) has no financial relationships with financial interests relating to the topic of this activity. In addition, the activity planners and managers have no financial relationships with financial interests relating to the topic of this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and The Body PRO do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and The Body PRO. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Purpose:
The purpose of this activity is to provide HIV physicians, pharmacists, nurses and other health care professionals with the opportunity to supplement their knowledge on issues related to complications of HIV and HIV treatment. This will be accomplished via a CME/CE summary of highlighted research from the 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008).
Target Audience:
This activity has been designed to meet the educational needs of physicians, pharmacists, nurses and other health care professionals involved in the care of patients with HIV.
Objectives:
Participants who complete this educational activity should be able to:
- Review the latest data from, and expert opinion regarding, key studies presented at CROI 2008 pertinent to the complications of HIV and HIV treatment.
- Outline CROI 2008 research regarding the use of growth-hormone replacement therapy or chromium to ameliorate body shape problems among HIV-infected patients.
- Cite findings presented at CROI 2008 regarding the relationship between the use of specific antiretrovirals and an increased risk of myocardial infarction among HIV-infected patients.
- Explain the significance of findings presented at CROI 2008 regarding the possible role of HIV infection in triggering a proinflammatory state.
- Describe noteworthy findings from CROI 2008 that focus on issues of mortality and aging.
This activity is no longer available for CME/CE credit.